Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemiaKevin R. Kelly, Swaminathan P. Iyer|Investigational New Drugs|2013Cited by 78
The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinibKevin R. Kelly, Jennifer S. Carew|Journal of Cellular and Molecular Medicine|2010Cited by 72
Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO‐dependent mechanismKevin R. Kelly, Jennifer S. Carew|International Journal of Cancer|2012Cited by 53
Exploring treatment-driven subclonal evolution of prognostic triple biomarkers: Dual gene fusions and chimeric RNA variants in novel subtypes of acute myeloid leukemia patients with KMT2A rearrangementYi Xu, Jiang F. Zhong, Jeffrey Xiao et al.|Drug Resistance Updates|2025Cited by 3